MiR-141 was also found to be overexpressed in ovarian and colorectal cancers [23, 24] and downregulated in prostate, hepatocellular, renal cell carcinoma and in gastric cancer tissues [25] [26] [27] [28] raising a controversial issue about the role of miR-141 in cancer progression.